ModifiedBlue Cross Blue Shield - OklahomaPolicy CPCPLAB037

Serum Tumor Markers for Malignancies

Defines reimbursement criteria for measurement of serum tumor markers for specified malignancy indications and lab management reimbursement rules that affect providers submitting claims to Blue Cross Blue Shield of Oklahoma.

Policy Summary

PayerBlue Cross Blue Shield - Oklahoma

PolicySerum Tumor Markers for Malignancies

Policy CodePolicy CPCPLAB037

Change TypeCode additions and marker-specific reimbursement revisions

Effective DateOct 1, 2025

Next Review Date

Key ActionSubmit claims with accurate documentation and use valid code combinations; reference the updated code list and reimbursement tables when submitting claims.

SourceLink

POLICY UPDATE CHANGES

Added code 0599U effective 10/01/2025.

Expanded and detailed numerous marker-specific indications and monitoring frequencies (examples: AFP, CA-125, CA 19-9, CEA, calcitonin, B2M, LDH, serum free light chain, BNP/NT-proBNP).

Added code 83521.

Added code 0404U on 03/01/2024 and previously added code 0599U (10/01/2025) noted.

multiplemarker-specific reimbursement updates in this update history

3recent CPT/HCPCS/other code additions referenced

codes listedprocedure/CPT and other codes provided in policy

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

biomarkers not reimbursable

08/01/2025most recent policy update date listed

Reimbursable Serum Tumor Marker Indications and Limits

Reimbursable markers and indications

Listed serum tumor markers may be reimbursable when used for the specified clinical indications and at specified frequencies; other uses and markers are excluded.

Except where otherwise specified, quarterly measurement of designated serum tumor markers is permitted for follow-up, monitoring, and/or surveillance.

ALL of the following

Alkaline phosphatase (ALP)
- Indications: Bone neoplasms — workup; during treatment; surveillance.
- Indication: Systemic light chain amyloidosis — initial diagnostic workup.

ALL of the following

Alpha fetoprotein (AFP)
- Indications: Hepatocellular carcinoma — screening; workup for confirmed HCC; surveillance every 3-6 months for 2 years, then every 6 months.
- Indication: Intrahepatic cholangiocarcinoma — workup for isolated intrahepatic mass.
- Indication: Occult primary — additional workup for localized adenocarcinoma or carcinoma not otherwise specified (liver, mediastinum, or retroperitoneal mass).
- Indications: Ovarian/fallopian tube/primary peritoneal cancer — initial workup; during primary chemotherapy; monitoring/follow-up for complete response as clinically indicated; monitoring for various less common ovarian subtypes as listed in the reimbursement table.

ALL of the following

Beta human chorionic gonadotropin (beta-HCG)
- Indications: Gestational trophoblastic neoplasia — initial workup; during and post treatment (no more than weekly); follow-up/surveillance (no more than monthly for 12 months).
- Indication: Occult primary — additional workup; individuals <65 with testicular presentation with retroperitoneal mass.
- Indications: Ovarian/fallopian tube/primary peritoneal cancer — initial workup; during primary chemotherapy; monitoring/follow-up.
- Indications: Testicular cancer (non-seminoma and pure seminoma) — diagnostic workup, risk classification, surveillance (no more than every 2 months).

ALL of the following

CA 19-9
- Indications include ampullary adenocarcinoma — workup; surveillance every 3-6 months for 2 years then every 6-12 months up to 5 years as clinically indicated for resected ampullary cancer stage I-III.
- Indications include appendiceal, extrahepatic cholangiocarcinoma, gallbladder cancer, intrahepatic cholangiocarcinoma, ovarian, pancreatic adenocarcinoma, small bowel adenocarcinoma — baseline workup and monitoring with specified post-treatment surveillance intervals.

ALL of the following

CA-125
- Indications include appendiceal adenocarcinoma — baseline workup and additional workup/surveillance if initially elevated; various gynecologic and peritoneal indications as specified in the reimbursement table.

ALL of the following

CEA
- Indications include appendiceal adenocarcinoma — baseline, monitoring, post-treatment surveillance; colon cancer — baseline, monitoring, surveillance intervals; invasive breast cancer — monitoring metastatic disease; and other GI/biliary monitoring as specified.

ALL of the following

Beta-2 microglobulin (B2M)
- Indications: B-cell lymphomas — workup; CLL/SLL — workup and prognostic/therapy determination; multiple myeloma — initial diagnostic workup and follow-up/surveillance as needed.

ALL of the following

Lactate dehydrogenase (LDH)
- Indications: B-cell lymphomas — workup; bone neoplasms — workup; CLL/SLL — workup and measurement at transformation/histologic progression if applicable; melanoma — workup for metastatic/recurrent disease; multiple myeloma — initial workup and surveillance as needed; additional ovarian cancer subtype monitoring additions noted in update history.

ALL of the following

Serum free light chain
- Indications: Multiple myeloma — initial diagnostic workup; surveillance up to once per month.
- Indication: Systemic light chain amyloidosis — initial diagnostic workup.

ALL of the following

Troponin T / NT-proBNP
- Indication: Systemic light chain amyloidosis — initial diagnostic workup (troponin T and NT-proBNP referenced).

Exclusions

For all other cancer indications not discussed above, use of the listed biomarkers (alone or in a panel) is not reimbursable.
All other serum tumor markers not addressed above (alone or in a panel) are not reimbursable.
Analysis of proteomic patterns in serum for screening and detection of cancer is not reimbursable.

Marker-specific reimbursement changes

Updates to reimbursement information include additions, removals, and frequency changes for specific tumor markers across cancer types.

ALL of the following

AFP: Added and modified monitoring/follow-up indications for multiple ovarian cancer subtypes; changed surveillance frequency for borderline ovarian epithelial tumors and other ovarian indications; removed some initial diagnostic indications for testicular cancer nonseminoma and sacrococcygeal teratomas.

ALL of the following

CA-125: Added baseline workup indication for appendiceal adenocarcinoma; added Lynch syndrome surveillance; updated monitoring frequency for borderline ovarian epithelial tumors to 'every visit if initially elevated'.

ALL of the following

CA 19-9:

Procedure, Assay, and Reimbursement Codes

Procedure/assay codesmixed

81500
81503
81538
81599
82105
82107
82232
82308
82378
83520

1–10 of 36

1/4

Recently added codes referenced in update historymixed

0404U	Added code (policy history).
0599U	Added code effective 10/01/2025 (policy history).
83521	Added code (policy history).

Surveillance frequency exceptions

AFP (alpha‑fetoprotein)Surveillance: every 3–6 months for 2 years, then every 6 months (when indicated) — specific surveillance intervals applied in HCC and selected ovarian indications.

CA 19‑9Surveillance: typically every 3–6 months for 2 years then every 6–12 months up to 5 years for select biliary and pancreatic/ampullary indications.

CA‑125Surveillance/monitoring: frequencies vary by indication; monitoring after treatment and for ovarian subtypes as clinically indicated (policy notes updated to 'every visit if initially elevated' for some borderline ovarian tumors).

CEASurveillance/monitoring: used for baseline and post‑treatment surveillance in colorectal and other GI cancers with specified monitoring intervals per clinical indication.

General policy ruleExcept where otherwise specified above, quarterly measurement of designated serum tumor markers is the standard permitted frequency unless an exception is listed.

Claims Submission, Billing Notes, and Product References

Documentation Required

Provider obligations and claim documentation

If a conflict arises between this policy and any plan document under which a member is entitled to Covered Services, the plan document governs. If a conflict arises between this Clinical Payment and Coding Policy and any provider contract pursuant to which a provider participates in and/or provides Covered Services, the provider contract governs. Plan documents include, but are not limited to, Certificates of Health Care Benefits, benefit booklets, Summary Plan Descriptions, and other coverage documents. Blue Cross and Blue Shield of Oklahoma may use reasonable discretion interpreting and applying this policy to services being delivered in a particular case. BCBSOK has full and final discretionary authority for interpretation and application to the extent provided under any applicable plan documents.

Providers are responsible for submission of accurate documentation of services performed.
Submit claims using valid code combinations from HIPAA-approved code sets and code appropriately per industry coding guidelines (e.g., UB, AMA CPT, CPT Assistant, HCPCS, ICD-10-CM/PCS, NDC, DRG guidelines, CMS NCCI Policy Manual and edits).
Claims are subject to code edit protocols and adjudication logic; providers may be asked to submit additional documentation upon request.

Note

Key Terms and Marker Definitions

Lab management reimbursement criteria — description

PurposeDefines lab management reimbursement criteria that govern reimbursement for certain serum tumor marker measurements.

ApplicabilityNot all requirements apply to each product; providers should review Plan documents for eligible coverage for services rendered.

Standard frequencyWhere not otherwise specified, quarterly measurement of designated serum tumor markers is permitted per the policy table.

Plan document precedence

Precedence of plan documentsIf a conflict arises between this Clinical Payment and Coding Policy and any plan document under which a member is entitled to Covered Services, the plan document will govern.

Provider contractsIf a conflict arises between this policy and any provider contract, the provider contract will govern.

Policy Summary

PayerBlue Cross Blue Shield - Oklahoma

PolicySerum Tumor Markers for Malignancies

Policy CodePolicy CPCPLAB037

Change TypeCode additions and marker-specific reimbursement revisions

Effective DateOct 1, 2025

Next Review Date

Key ActionSubmit claims with accurate documentation and use valid code combinations; reference the updated code list and reimbursement tables when submitting claims.

SourceLink

On This Page

Added ampullary adenocarcinoma and appendiceal adenocarcinoma workup; added monitoring indications for extrahepatic cholangiocarcinoma and gallbladder cancer; removed hepatocellular carcinoma initial diagnostic indication.

ALL of the following

CEA: Added monitoring indications for appendiceal adenocarcinoma and multiple GI/biliary cancers; updated ovarian tumor monitoring frequencies (borderline ovarian epithelial tumors to every visit if initially elevated).

ALL of the following

Calcitonin (CALCA): For medullary carcinoma replaced 'initial diagnostic evaluation' with 'additional workup' and added post-surgical evaluation; added workup indications for adenocarcinoma, anaplastic/undifferentiated epithelial tumors, and occult primary.

ALL of the following

Beta-2 microglobulin (B2M): Added prognostic/therapy determination indications for CLL/SLL; removed some prognostication indications for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.

ALL of the following

LDH: Multiple updates including additions for ovarian cancer subtypes (carcinosarcoma, clear cell, grade 1 endometrioid, mucinous neoplasms, low-grade serous carcinoma) to include monitoring/follow-up; removals of some initial diagnostic indications for leukemias and myeloproliferative neoplasms; added measurement at transformation for CLL/SLL.

ALL of the following

Serum free light chain: Changed surveillance frequency for multiple myeloma from 'as needed' to once per month.

ALL of the following

BNP / NT-proBNP: Added indication for initial diagnostic workup in multiple myeloma.

ALL of the following

Inhibin (INHA): Updated monitoring/ follow-up frequency for borderline ovarian epithelial tumors to 'every visit if initially elevated'; added other inhibin indication changes and removed some undiagnosed pelvic mass initial evaluation indications.

Serum free light chain surveillance

Multiple myeloma surveillanceSerum free light chain measurement may be used for surveillance up to once per month.

Initial diagnostic useSerum free kappa and lambda light chains are indicated for initial diagnostic workup of multiple myeloma and systemic light chain (AL) amyloidosis.

Other hematologic usesFree light chain testing is also used in workup for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma and as needed for follow‑up in multiple myeloma.

Product references in bibliography

References to commercial diagnostic products included in the bibliography are provided for informational purposes and do not imply endorsement. Providers should consult product manufacturers and peer-reviewed literature for current product information.

Commercial product references in this policy bibliography include OVA1 and OvaWatch.

Billing Rule

Billing and claim submission note

Billing codes and reimbursement guidance have been updated — review claim coding and billing practices to avoid denials and ensure appropriate reimbursement.

Added HCPCS/CPT code 0599U effective 10/01/2025 — verify correct use and medical necessity documentation when billing.
Providers should review the Reimbursement Information updates (08/01/2025 revision effective 10/01/2025) for marker-specific reimbursement changes and updated indications (e.g., AFP, B2M, CALCA, CA 15-3/27.29, CA 19-9).
Ensure claims reflect updated indication-to-code mapping and supporting documentation; submit any requested clinical records promptly to support adjudication.

Examples of plan documentsPlan documents include Certificates of Health Care Benefits, benefit booklets, Summary Plan Descriptions, and other coverage documents.

Free light chains (sFLC) — definition and clinical use

AnalytesSerum free kappa and free lambda immunoglobulin light chains.

Clinical useUsed for detection and monitoring of monoclonal gammopathies including multiple myeloma and systemic light chain (AL) amyloidosis.

Role in prognosis and monitoringCorrelates with disease burden and may be used for diagnostic workup, prognostic assessment, and surveillance (frequency described elsewhere in policy).

AFP / AFP‑L3 / PIVKA‑II — definitions and use

AFP (alpha‑fetoprotein)A serum tumor marker used in detection and surveillance of hepatocellular carcinoma; includes AFP‑L3 fraction assessments referenced in literature for prognostic/diagnostic value.

PIVKA‑IIPIVKA‑II (des‑gamma carboxy prothrombin) is referenced along with AFP and AFP‑L3 as markers used in HCC detection and surveillance.

Clinical roleAFP, AFP‑L3, and PIVKA‑II are referenced in the policy and cited literature as part of HCC workup and surveillance strategies.

CA125, HE4, CA19‑9, CEA — definitions and intended uses

CA‑125A tumor‑associated antigen commonly used in evaluation and monitoring of ovarian and peritoneal malignancies; used in baseline workup and post‑treatment monitoring as indicated.

HE4Often combined with CA‑125 in diagnostic evaluations for ovarian tumors (combined marker utility cited in literature).

CA 19‑9 and CEACA 19‑9 and CEA are gastrointestinal tumor‑associated antigens referenced for evaluation and monitoring of pancreatic, biliary, colorectal and other GI malignancies and may be used in combined panels per clinical indication.

NACB laboratory medicine practice guidelines (citation)

Guideline citationNational Academy of Clinical Biochemistry (NACB) laboratory medicine practice guidelines for use of tumor markers in clinical practice (Clin Chem 2008) are cited in the policy.

Quality requirementsNACB guidance referenced includes laboratory quality requirements and practice recommendations for tumor marker use.

ScopeNACB publications cited address tumor marker use across multiple cancer types and provide foundational practice guidance referenced in the policy bibliography.